Vivos Therapeutics Inc. (VVOS)
undefined
undefined%
At close: undefined
4.76
2.59%
After-hours Dec 13, 2024, 07:58 PM EST

Company Description

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children.

The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada.

Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

Vivos Therapeutics Inc.
Vivos Therapeutics Inc. logo
Country United States
IPO Date Dec 11, 2020
Industry Medical - Devices
Sector Healthcare
Employees 114
CEO R. Kirk Huntsman

Contact Details

Address:
9137 Ridgeline Boulevard
Highlands Ranch, Colorado
United States
Website https://vivos.com

Stock Details

Ticker Symbol VVOS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001716166
CUSIP Number 92859E108
ISIN Number US92859E2072
Employer ID 81-3224056
SIC Code 3841

Key Executives

Name Position
R. Kirk Huntsman Co-Founder, Chairman of the Board & Chief Executive Officer
Bradford K. Amman Chief Financial Officer, Treasurer & Secretary
John Ballard Senior Vice President of Technology
Nicholas M. DeGennaro Senior Vice President of Medical Integration Division
RaeAnn Byrnes Co-Founder and Senior Vice President of Events & Clinical Advisory Services
Ruth Hembree Senior Vice President of Practice Services
Stephanie Huebner Senior Vice President of Dental Service Integration
Susan McCullough Co-Founder & Executive Vice President of Operations
Todd Huntsman Co-Founder & Senior Vice President of Product and Technology

Latest SEC Filings

Date Type Title
Nov 27, 2024 8-K Current Report
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 06, 2024 DEFA14A Filing
Oct 07, 2024 DEF 14A Filing
Sep 24, 2024 SC 13G Statement of acquisition of beneficial ownership b...